Stephens Consulting’s Recursion Pharmaceuticals RXRX Stock Holding History

Stephens Consulting’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$275	Hold	67	–	–	﹤0.01%	447
2025 Q3	$327	Hold	67	–	–	﹤0.01%	377
2025 Q2	$340	Sell	67 -120	-64%	-$590	﹤0.01%	995
2025 Q1	$990	Buy	187 +120	+179%	+$875	﹤0.01%	649
2024 Q4	$453	Buy	+67	New	+$450	﹤0.01%	501

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Stephens Consulting's RXRX Position: Q4 2025 in Review

Stephens Consulting held its Recursion Pharmaceuticals (RXRX) position steady in Q4 2025 at 67 shares worth $275. The position accounts for ﹤0.01% of the portfolio, ranked #447.

Stephens Consulting first reported a position in RXRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $990 in Q1 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Stephens Consulting held 67 shares of Recursion Pharmaceuticals worth $275 as of Q4 2025.
Stephens Consulting left its Recursion Pharmaceuticals share count unchanged in Q4 2025.
Recursion Pharmaceuticals made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #447 holding.
Stephens Consulting first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
Stephens Consulting's Recursion Pharmaceuticals position peaked at $990 in Q1 2025.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.